Combination Intravesical Therapy
Nathan A Brooks1, Michael A O'Donnell1
1Department of Urology, The University of Iowa Hospitals and Clinics, 200 Hawkins Drive, Iowa City, IA, USA.
Abstract:
After Bacillus Calmette-Guerin (BCG) failure, there is likely a 6- to 24-month window whereby salvage intravesical therapy might allow for preservation of the bladder without disease worsening. Combination intravesical, salvage therapy for nonmuscle invasive bladder cancer represents a promising avenue for treatment in patients unfit or unwilling to undergo cystectomy. BCG with concomitant immune stimulating agents or immune checkpoint inhibitors, combination chemotherapy regimens, such as gemcitabine and docetaxol, and novel agents currently in clinical trials provide hope for a bladder-sparing alternative for patients after BCG failure.
Related Concept Videos
Urinary Tract Calculi III: Medical Management
Urinary Tract Calculi VI: Surgical Management
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Imaging Studies V: Intravenous Urography and Retrograde Pyelography
Imaging Studies VI: Voiding Cystourethrography and Cystography
Urinary Tract Infection IV: Nursing Management


